| 422 | 4 | 27 |
| 下载次数 | 被引频次 | 阅读次数 |
为了解深圳境外输入的新型冠状病毒(SARS-CoV-2)的遗传特征,本研究对2021年2月六株境外输入的SARS-CoV-2毒株进行了高通量测序与基因组序列分析。测序获得的六株SARS-CoV-2毒株基因组长度分别为29 450 nt、28 936 nt、28 875 nt、29 855 nt、29 146 nt和29 528 nt。根据"Pango lineages"分型法,三个来自肯尼亚、南非和柬埔寨的毒株属于B.1.1.7系(VOC-202012/01),一个来自美国的毒株属于B.1.2系(美国谱系),两个来自南非和肯尼亚的毒株属于B.1.351系(20H/501Y.V2)。与武汉毒株Wuhan-Hu-1(NC_045512.2)比较,B.1.1.7系毒株的刺突蛋白(S)中发现了多达10个氨基酸的变异,B.1.2系毒株的S蛋白仅发现一个氨基酸的变异,B.1.351系毒株的S蛋白中发现了多达11个氨基酸的变异。来自柬埔寨的一株B.1.1.7系毒株的S蛋白中发现了三个变异(H69S,V70I与Y144V)与另外两个B.1.1.7系毒株中的变异(H69del,V70del与Y144del)不同。六个毒株在ORF1b上都表现出了P314L的变异,在S蛋白上都表现出了D614G的变异。2021年2月深圳输入了传染性更强的B.1.1.7英国变异株和B.1.351南非变异株。境外输入的SARS-CoV-2变异株存在引起本地暴发与流行的风险,需持续对境外输入的SARS-CoV-2毒株进行分子监测。
Abstract：In this study,high-throughput sequencing and genome sequence analysis were performed for six imported SARS-CoV-2 strains in Shenzhen to investigate their genetic characteristics. The six genome sequences obtained in the study were 29,450 nucleotides(nt),28,936 nt,28,875 nt,29,855 nt,29,146 nt and 29,528 nt in length,respectively. Three strains from Kenya,South Africa,and Cambodia,one strain from USA, and two strains from South Africa and Kenya were assigned to lineages B. 1.1.7(variant of concern[VOC]-202012/01),B.1.2(USA lineage),and B.1.351(20 H/501 Y.V2),respectively based on the"Pango lineages"rule. As many as ten amino acid(AA)differences were observed in the Spike(S)protein of the lineage B. 1.1.7 strains when compared to the reference strain Wuhan-Hu-1(NC_045512.2);only one AA difference was found in the S protein of the lineage B. 1.2 strain,and as many as 11 AA differences were observed in the S protein of the lineage B.1.351 strains. Mutations(H69 S,V70 I and Y144 V)in the S protein of the B.1.1.7 lineage strain from Cambodia were different from those(H69 del,V70 del,and Y144 del)in the S protein of the other two B.1.1.7 lineage strains. Mutations P314 L in ORF1 b region and D614 G in the S protein were observed in all the SARS-CoV-2 strains determined in this study. In conclusion,variants VOC 202012/01 and GH/501 Y.V2 with increased infectivity were imported into Shenzhen in February 2021.There is a risk that imported SARS-CoV-2 variants may cause local outbreaks and epidemics. Continuous molecular surveillance for imported SARS-CoV-2 is essential in Shenzhen..
[1]Wu F,Zhao S,Yu B,Chen Y M,Wang W,Song Z G,Hu Y,Tao Z W,Tian J H,Pei YY,Yuan M L,Zhang YL,Dai F H,Liu Y,Wang Q M,Zheng J J,Xu L,Holmes E C,Zhang Y Z.A new coronavirus associated with human respiratory disease in China[J].Nature,2020,579(7798):265-269.
[2]毛亚萍,卞大伟.SARS-CoV-2毒株S蛋白突变及其影响的生物信息学分析[J].病毒学报,2020,36(6):1020-1026.
[3]刘晓瑜,魏永伟.SARS-CoV-2 S蛋白：研究进展与挑战[J].病毒学报,2020,36(6):1157-1164.
[4]郭建淑,张燕,孙学春,钟萍.新型冠状病毒受体血管紧张素转化酶2的研究进展[J].病毒学报,2020,36(6):1165-1170.
[5]Coutard B,Valle C,Lamballerie X de,Canard B,Seidah N G,Decroly E.The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade[J].Antiviral Res,2020,176:104742.
[6]Wu C,Zheng M,Yang Y,Gu X,Yang K,Li M,Liu Y,Zhang Q,Zhang P,Wang Y,Wang Q,Xu Y,Zhou Y,Zhang Y,Chen L,Li H.Furin:A Potential Therapeutic Target for COVID-19[J].iScience,2020,23(10):101642.
[7]宋洋,许文波.新型冠状病毒基因组序列的网络平台与基因分型[J].病毒学报,2020,37(01):181-190.
[8]Rambaut A,Holmes E C,O'Tooleá,Hill V,McCrone J T,Ruis C,du Plessis L,Pybus O G.Addendum:A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology[J].Nat Microbiol,2021,6(3):415.
[9]Galloway S E,Paul P,MacCannell D R,Johansson MA,Brooks J T,MacNeil A,Slayton R B,Tong S,Silk B J,Armstrong G L,Biggerstaff M,Dugan V G.Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States,December 29,2020-January 12,2021[J].MMWR Morb Mortal Wkly Rep,2021,70(3):95-99.
[10]Tegally H,Wilkinson E,Giovanetti M,Iranzadeh A,Fonseca V,Giandhari J,Doolabh D,Pillay S,San EJ,Msomi N,Mlisana K,Gottberg A,Walaza S,Allam M,Ismail A,Mohale T,Glass AJ,Engelbrech S,Zyl G V,Preiser W,Petruccione F,Sigal A,Hardie D,Marais D,Hsiao M,Korsman S,Davies MA,Tyers L,Mudau I,York D,Maslo C,Goedhals D,Abrahams S,Laguda-Akingba O,Alisoltani-Dehkordi A,Godzik A,Wibmer C K,Sewell B T,Louren?o J,Alcantara L C J,Pond S L K,Weaver S,Martin D,Lessells R J,Bhiman J N,Williamson C,Oliveira T.Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2(SARS-CoV-2)lineage with multiple spike mutations in South Africa.medRxiv 2020.12.21.20248640;doi:https：//doi.org/10.1101/2020.12.21.20248640
[11]沈思鹏,魏永越,赵杨,姜玥,官锦兴,陈峰.全球新型冠状病毒肺炎疫情对我国的输入风险评估[J].中华流行病学杂志,2020,41(10):1582-1587.
[12]Kumar S,Stecher G,Li M,Knyaz C,and Tamura K.MEGA X:Molecular Evolutionary Genetics Analysis across computing platforms[J].Mol Biol Evol,2018,35(6):1547-1549.
[13]Hodcroft E B,Domman D B,Snyder D J,Oguntuyo K,Van Diest M,Densmore K H,Schwalm K C,Femling J,Carroll J L,Scott R S,Martha M W,Edwards M D,Hull N C,Kevil C G,Vanchiere J A,Lee B,Dinwiddie D L,Cooper V S,Kamil J P.Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677.medRxiv 2021.02.12.21251658;doi:https：//doi.org/10.1101/2021.02.12.21251658.Preprint.
[14]Public Health England.Technical briefing 8:SARS-CoV-2 variants of concern and variants under investigation in England[R].UK:Public Health England,2021.
[15]Kemp S A,Harvey W T,Lytras S,The COVID-19Genomics UK(COG-UK)consortium,Carabelli A M,Robertson D L,Gupta R K.Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70.bioRxiv 2020.12.14.422555;doi:https：//doi.org/10.1101/2020.12.14.422555.Preprint.
[16]McCarthy K R,Rennick L J,Nambulli S,RobinsonMcCarthy L R,Bain W G,Haidar G,Duprex W P.Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape.Science,2021,371(6534):1139-1142.
[17]Andreano E,Piccini G,Licastro D,Casalino L,Johnson N V,Paciello I,Monego SD,Pantano E,Manganaro N,Manenti A,Manna R,Casa E,Hyseni I,Benincasa L,Montomoli E,Amaro R E,McLellan JS,Rappuoli R.SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma.bioRxiv 2020 Dec 28:2020.12.28.424451.DOI:10.1101/2020.12.28.424451.Preprint.
[18]Jangra S,Ye C,Rathnasinghe R,Stadlbauer D,Krammer F,Simon V,Martinez-Sobrido L,GarciaSastre A,Schotsaert M.The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and postvaccination sera.medRxiv 2021,29:2021.01.26.DOI:10.1101/2021.01.26.21250543.Preprint.
[19]Starr T N,Greaney A J,Hilton S K,Ellis D,Crawford K H D,Dingens A S,Navarro M J,Bowen JE,Tortorici M A,Walls A C,King N P,Veesler D,Bloom J D.Deep Mutational Scanning of SARS-CoV-2Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.Cell,2020,182(5):1295-1310.
[20]Hou Y J,Chiba S,Halfmann P,Ehre C,Kuroda M,Dinnon K H,Leist S R,Sch?fer A,Nakajima N,Takahashi K,Lee R E,Mascenik T M,Graham R,Edwards C E,Tse L V,Okuda K,Markmann A J,Bartelt L,de Silva A,Margolis D M,Boucher R C,Randell S H,Suzuki T,Gralinski L E,Kawaoka Y,Baric R S.SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo[J].Science,2020,370(6523):1464-1468.
[21]Korber B,Fischer W M,Gnanakaran S,Yoon H,Theiler J,Abfalterer W,Hengartner N,Giorgi E E,Bhattacharya T,Foley B,Hastie K M,Parker M D,Partridge D G,Evans C M,Freeman T M,de Silva TI;Sheffield COVID-19 Genomics Group,McDanal C,Perez L G,Tang H,Moon-Walker A,Whelan S P,LaBranche C C,Saphire E O,Montefiori D C.Tracking Changes in SARS-CoV-2 Spike:Evidence that D614G Increases Infectivity of the COVID-19 Virus[J].Cell,2020,182(4):812-827.
[22]Zhang L,Jackson C B,Mou H,Ojha A,Peng H,Quinlan B D,Rangarajan E S,Pan A,Vanderheiden A,Suthar M S,Li W,Izard T,Rader C,Farzan M,Choe H.SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity[J].Nat Commun,2020,11(1):6013.
[23]Zhou B,Thi Nhu Thao T,Hoffmann D,Taddeo A,Ebert N,Labroussaa F,Pohlmann A,King J,Steiner S,Kelly J N,Portmann J,Halwe N J,Ulrich L,Trüeb B S,Fan X,Hoffmann B,Wang L,Thomann L,Lin X,Stalder H,Pozzi B,de Brot S,Jiang N,Cui D,Hossain J,Wilson M,Keller M,Stark T J,Barnes JR,Dijkman R,Jores J,Benarafa C,Wentworth D E,Thiel V,Beer M.SARS-CoV-2 spike D614G change enhances replication and transmission[J].Nature,2021,592(7852):122-127.
[24]Hoffmann M,Kleine-Weber H,P?hlmann S.AMultibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.Mol Cell,2020,78(4):779-784.
[25]Davies N G,Abbott S,Barnard R C,Jarvis C I,Kucharski A J,Munday J D,Pearson C A B,Russell TW,Tully D C,Washburne A D,Wenseleers T,Gimma A,Waites W,Wong K L M,van Zandvoort K,Silverman J D;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium,Diaz-Ordaz K,Keogh R,Eggo R M,Funk S,Jit M,Atkins K E,Edmunds W J.Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England[J].Science,2021,372(6538):eabg3055.
[26]Davies N G,Jarvis C I;CMMID COVID-19 Working Group,Edmunds W J,Jewell N P,Diaz-Ordaz K,Keogh R H.Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7[J].Nature,2021,593(7858):270-274.
[27]Wang P,Nair M S,Liu L,Iketani S,Luo Y,Guo Y,Wang M,Yu J,Zhang B,Kwong P D,Graham B S,Mascola J R,Chang J Y,Yin M T,Sobieszczyk M,Kyratsous CA,Shapiro L,Sheng Z,Huang Y,Ho DD.Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.Nature,2021,593(7857):130-135.
[28]Chen H,Huang X,Zhao X,Song Y,Hao P,Jiang H,Zhang X,Fu C.The First Case of New Variant COVID-19 Originating in the United Kingdom Detected in a Returning Student-Shanghai Municipality,China,December 14,2020[J].China CDC Weekly,2021,3(1):1-3.
[29]Chen F,Li B,Hao P,Song Y,Xu W,Liu N,Lei C,Ke C.A Case of New Variant COVID-19 First Emerging in South Africa Detected in Airplane PilotGuangdong Province,China,January 6,2021[J].China CDC Weekly,2021,3(2):28-29.
[30]Cheng C,Wang L,Lyu Z,Peng B,Li Y,Kong D,Zuo L,Zhang X M,Yang C,Liu W,Wan J,Tang Y,He J,Wen Y,Xu S,Wu W,Chen Y,Liu G,Xia J,Zou X,Zhang R,Hu Q,Mei S,Feng T.Four COVID-19 Cases of New Variant B.1.351 First Emerging in South Africa in Chinese Passengers on Same FlightShenzhen,China,January 2021[J].China CDCWeekly,2021,3(8):175-177.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.003977
中图分类号:R373
引用信息:
[1]陈龙,房师松,梅树江,等.2021年2月深圳市六株境外输入的SARS-CoV-2基因组特征分析[J].病毒学报,2021,37(03):515-526.DOI:10.13242/j.cnki.bingduxuebao.003977.
基金信息:
深圳市科技创新委员会新型冠状病毒肺炎疫情专项(项目号：JSGG20200207161926465),题目：2019-nCoV主要传播途径及其病毒在人体不用样本中的排毒规律研究;深圳市科技创新委员会技术攻关重点项目(项目号：JSGG20200225152648408),题目：基于SARS-CoV-2冠状病毒表面Spike蛋白的早期快检技术研发;深圳市科技创新委员会技术攻关面上项目(项目号：JSGG20191129144225464),题目：重20200162基于宏病毒组技术的快速诊断技术研发; 广东省自然科学基金面上项目(项目号：2019A1515010394),题目：E3泛素连接酶RNF86负向调控EV71感染手足口病固有免疫反应的机制研究~~
2021-04-27
2021
2021-05-24
2021
1
2021-05-25
2021-05-25
2021-05-25